ENZND — Enzon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Enzon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.701 | 0.026 | 0 | 0.026 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 1.17 | 1.06 | 1.04 | 1.35 | 5.31 |
| Operating Profit | -0.469 | -1.03 | -1.04 | -1.33 | -5.31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.462 | -0.386 | 1.22 | 1.13 | -3.39 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.469 | -0.186 | 1.37 | 0.778 | -3.41 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.469 | -0.186 | 1.37 | 0.778 | -3.41 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.49 | -1.46 | 0.098 | -0.497 | -5.53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.36 | -1.97 | 0.132 | -0.67 | -7.46 |